Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Oakman

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Ode to a past emperorAngelo Di Leo, Catherine Oakman
Current Opinion in Oncology|August 29, 2009
Predicting anthracycline benefit: have we made any progress?Erica Moretti, Catherine Oakman, Angelo Di Leo
Breast (Edinburgh, Scotland)|April 13, 2010
Management of triple negative breast cancerCatherine Oakman, Giuseppe Viale, Angelo Di Leo
Nature Reviews. Clinical Oncology|October 27, 2010
Breast cancer assessment tools and optimizing adjuvant therapyCatherine Oakman, Libero Santarpia, Angelo Di Leo
Breast Cancer Research and Treatment|June 16, 2010
Re-searching anthracycline therapyCatherine Oakman, Erica Moretti, Angelo Di Leo
Future Oncology (London, England)|February 25, 2011
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancerCatherine Oakman, Erica Moretti, Libero Santarpia, et al.
Future Oncology (London, England)|February 21, 2022
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancerChristine Muttiah, James R Whittle, Catherine Oakman, et al.
Cancer Management and Research|December 29, 2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancerCatherine Oakman, Marta Pestrin, Elena Zafarana, et al.
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Ode to a past emperorAngelo Di Leo, Catherine Oakman
Current Opinion in Oncology|August 29, 2009
Predicting anthracycline benefit: have we made any progress?Erica Moretti, Catherine Oakman, Angelo Di Leo
Breast (Edinburgh, Scotland)|April 13, 2010
Management of triple negative breast cancerCatherine Oakman, Giuseppe Viale, Angelo Di Leo
Nature Reviews. Clinical Oncology|October 27, 2010
Breast cancer assessment tools and optimizing adjuvant therapyCatherine Oakman, Libero Santarpia, Angelo Di Leo
Breast Cancer Research and Treatment|June 16, 2010
Re-searching anthracycline therapyCatherine Oakman, Erica Moretti, Angelo Di Leo
Future Oncology (London, England)|February 25, 2011
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancerCatherine Oakman, Erica Moretti, Libero Santarpia, et al.
Future Oncology (London, England)|February 21, 2022
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancerChristine Muttiah, James R Whittle, Catherine Oakman, et al.
Cancer Management and Research|December 29, 2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancerCatherine Oakman, Marta Pestrin, Elena Zafarana, et al.
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Pageof 3